Sirolimus for Primary Antiphospholipid Syndrome: A Safety and Effectiveness Study
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests whether the drug sirolimus (Rapamune) is safe and effective for people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may offer a new option for those whose current treatment is stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have antiphospholipid syndrome (APS) diagnosed by a standard set of criteria.
- You must be on a stable combination of other treatments for APS.
- You cannot have had a serious allergic reaction to sirolimus or be on certain medications for chronic infections.
- You cannot be pregnant, planning pregnancy, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
Hear when a new Primary Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.